Biotech M&A Poised for Second‑Busiest Year, Early Deals Surge
Biotech M&A on track to have 2nd most active year in history w/ more early stage deals. Nice summary of which funds have benefited from recent M&A from Stifel @TimOpler $XBI $IBB https://t.co/udCuhIcaIi
Eli Lilly Acquires Centessa for $7.8B in Neuro Push
Lilly buying $CNTA Centessa (hub & spoke R&D co) for $6.3B + $1.5B CVR. Another neuro deal. Big congrats to @Medicxi, Index ventures, General Atlantic https://t.co/jkC9dv6d3I @medicx
First Full GlyphAllo Data Reveal From Discovery to Human Proof‑of‑Concept
Proud of the work of our Seaport team & collaborators published today in @ScienceTM. This ~13 page peer reviewed paper is the first comprehensive data disclosure of our GlyphAllo™ program from discovery through initial human proof‑of‑concept.
Amy Burrough
Adding $TERN to this list (Merck $6.7B reported) led by Amy Burroughs. Congrats to Amy and team 💪 https://t.co/KZ8CtA2GA0?
Seeking Examples of Overly Negative Biotech Trade Press
Will ask colleagues to respond because I haven’t been tracking all the tickers. Pls reply with examples of biotech trade press being called too negative
China's Asset Prices Rise, Ending Bargain-Basement Era
Assets from China are ubiquitous but China is no longer the 'bargain basement' in terms of deals. Will be interesting to see how rising prices impact deal interest https://t.co/yM3P28QCDc $XBI $IBB $BBC https://t.co/W61XACPX7O
Daré Bioscience Launches Reg A Crowdfunding for Women's Health
Daré Bioscience with an approved product and a pipeline in women’s health is raising money from investors in a crowdfunding like construct (reg A offering with minimum investment of $250). https://t.co/NA3JKe6Irg haven’t seen too many of these
